WallStreetZenWallStreetZen

NASDAQ: GNPX
Genprex Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their GNPX stock forecasts and price targets.

Forecast return on equity

Is GNPX forecast to generate an efficient return?

Company
-346.85%
Industry
11.71%
Market
329.83%
GNPX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GNPX forecast to generate an efficient return on assets?

Company
-74.75%
Industry
12.54%
GNPX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GNPX earnings per share forecast

What is GNPX's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$1.28-102.48%
Avg 2 year Forecast
-$1.17-102.28%

GNPX revenue forecast

What is GNPX's revenue in the next 2 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0

GNPX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GNPX$2.84N/AN/A
LYRA$3.64$16.00+340.17%Hold
CDIO$3.52N/AN/A
ADXN$8.10N/AN/A
REVB$1.05N/AN/A
View Top Biotech Stocks

Genprex Stock Forecast FAQ

What is GNPX's earnings growth forecast for 2025-2026?

(NASDAQ: GNPX) Genprex's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 207.38%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 2,953.18%.

Genprex's earnings in 2025 is -$17,046,323.On average, 3 Wall Street analysts forecast GNPX's earnings for 2025 to be -$2,894,691, with the lowest GNPX earnings forecast at -$2,781,174, and the highest GNPX earnings forecast at -$2,979,829.

In 2026, GNPX is forecast to generate -$2,663,116 in earnings, with the lowest earnings forecast at -$2,558,680 and the highest earnings forecast at -$2,741,443.

If you're new to stock investing, here's how to buy Genprex stock.

What is GNPX's revenue growth forecast for 2025-2026?

(NASDAQ: GNPX) Genprex's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 9,608.75%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,453.97%.

Genprex's revenue in 2025 is $0.On average, 4 Wall Street analysts forecast GNPX's revenue for 2025 to be $0, with the lowest GNPX revenue forecast at $0, and the highest GNPX revenue forecast at $0.

In 2026, GNPX is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is GNPX's forecast return on assets (ROA) for 2025-2026?

(NASDAQ: GNPX) forecast ROA is -74.75%, which is lower than the forecast US Biotechnology industry average of 12.54%.

What is GNPX's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: GNPX) Genprex's current Earnings Per Share (EPS) is $51.50. On average, analysts forecast that GNPX's EPS will be -$1.28 for 2025, with the lowest EPS forecast at -$1.23, and the highest EPS forecast at -$1.31. In 2026, GNPX's EPS is forecast to hit -$1.17 (min: -$1.13, max: -$1.21).

What is GNPX's forecast return on equity (ROE) for 2025-2026?

(NASDAQ: GNPX) forecast ROE is -346.85%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.